BioVaxys Acquires IMV’s Immunotherapy Tech for Growth
BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
- Latest
- Trending
BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
Stocks are set to open lower in New York as investors gear up for the first major inflation report of ...
The economic highlight of the week is the release of January's Consumer Price Index. Expectations are for a reading of ...
The core CPI is expected to rise 3.7% while the annualized change is at its lowest since May 2021. PPI ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.